SHL – Citi rates the stock as Downgrade to Sell

By Broker News | More Articles by Broker News

October’s Medicare stats indicated a grim industry outlook and now MYEFO has brought substantial cuts to pathology and imaging benefits. US Medicare has proposed changes to become effective in 2017 and Citi also expects a fee cut in Germany, all of which are negative for Sonic.

Citi has cut its FY16 earnings forecasts by 15-21% over FY16-18, leading to a reduction in target to $16.04 from $22.01 and a downgrade to Sell from Buy.

Sector: Health Care Equipment & Services.

Target price is $16.04.Current Price is $18.50. Difference: ($2.46) – (brackets indicate current price is over target). If SHL meets the Citi target it will return approximately -15% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →